198 related articles for article (PubMed ID: 11148482)
21. Differential effects of fluticasone and montelukast on allergen-induced asthma.
Palmqvist M; Bruce C; Sjöstrand M; Arvidsson P; Lötvall J
Allergy; 2005 Jan; 60(1):65-70. PubMed ID: 15575933
[TBL] [Abstract][Full Text] [Related]
22. Do the leukotriene receptor antagonists work in children with grass pollen-induced allergic rhinitis?
Keskin O; Alyamac E; Tuncer A; Dogan C; Adalioglu G; Sekerel BE
Pediatr Allergy Immunol; 2006 Jun; 17(4):259-68. PubMed ID: 16771779
[TBL] [Abstract][Full Text] [Related]
23. Leukotriene receptor antagonists (Montelukast) in the treatment of asthma crisis: preliminary results of a double-blind placebo controlled randomized study.
Ferreira MB; Santos AS; Pregal AL; Michelena T; Alonso E; de Sousa AV; Pereira E; Palma-Carlos AG
Allerg Immunol (Paris); 2001 Oct; 33(8):315-8. PubMed ID: 11763721
[TBL] [Abstract][Full Text] [Related]
24. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study.
Pei AY; Chan HH; Leung TF
Pediatr Allergy Immunol; 2001 Jun; 12(3):154-8. PubMed ID: 11473680
[TBL] [Abstract][Full Text] [Related]
25. Montelukast effects on inflammation in allergic rhinitis: a double blind placebo controlled pilot study.
Braido F; Riccio AM; Rogkakou A; Massacane P; Guerra L; Fumagalli F; Stagi E; Balestracci S; Porcu A; Canonica GW
Eur Ann Allergy Clin Immunol; 2012 Apr; 44(2):48-53. PubMed ID: 22768723
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity.
Papadopoulos NG; Philip G; Giezek H; Watkins M; Smugar SS; Polos PG
J Asthma; 2009 May; 46(4):413-20. PubMed ID: 19484680
[TBL] [Abstract][Full Text] [Related]
27. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis.
Bouchelouche K; Nordling J; Hald T; Bouchelouche P
J Urol; 2001 Nov; 166(5):1734-7. PubMed ID: 11586212
[TBL] [Abstract][Full Text] [Related]
28. Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting beta2-agonists: addition of montelukast in an open-label pilot study.
Dupont L; Potvin E; Korn D; Lachman A; Dramaix M; Gusman J; Peché R;
Curr Med Res Opin; 2005 Jun; 21(6):863-9. PubMed ID: 15969886
[TBL] [Abstract][Full Text] [Related]
29. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma.
Montuschi P; Mondino C; Koch P; Barnes PJ; Ciabattoni G
J Allergy Clin Immunol; 2006 Aug; 118(2):347-53. PubMed ID: 16890757
[TBL] [Abstract][Full Text] [Related]
30. Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis.
Meltzer EO; Philip G; Weinstein SF; LaForce CF; Malice MP; Dass SB; Santanello NC; Reiss TF
Am J Rhinol; 2005; 19(6):591-8. PubMed ID: 16402647
[TBL] [Abstract][Full Text] [Related]
31. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast.
Simons FE; Johnston L; Gu X; Simons KJ
Ann Allergy Asthma Immunol; 2001 Jan; 86(1):44-50. PubMed ID: 11206237
[TBL] [Abstract][Full Text] [Related]
32. Effect of montelukast on basophil releasability in patients with asthma.
Sade K; Kivity S; Fireman E; Schwartz Y; Kivity S
Isr Med Assoc J; 2005 Dec; 7(12):792-5. PubMed ID: 16382702
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis.
Virchow JC; Bachert C
Respir Med; 2006 Nov; 100(11):1952-9. PubMed ID: 16626955
[TBL] [Abstract][Full Text] [Related]
34. Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy.
Femiano F; Buonaiuto C; Gombos F; Lanza A; Cirillo N
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):402-7. PubMed ID: 19926502
[TBL] [Abstract][Full Text] [Related]
35. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%.
Becker A; Swern A; Tozzi CA; Yu Q; Reiss T; Knorr B
Curr Med Res Opin; 2004 Oct; 20(10):1651-9. PubMed ID: 15462699
[TBL] [Abstract][Full Text] [Related]
36. Responsiveness to montelukast is associated with bronchial hyperresponsiveness and total immunoglobulin E but not polymorphisms in the leukotriene C4 synthase and cysteinyl leukotriene receptor 1 genes in Korean children with exercise-induced asthma (EIA).
Lee SY; Kim HB; Kim JH; Kim BS; Kang MJ; Jang SO; Seo HJ; Hong SJ
Clin Exp Allergy; 2007 Oct; 37(10):1487-93. PubMed ID: 17883728
[TBL] [Abstract][Full Text] [Related]
37. Leukotriene receptor antagonists--a novel therapeutic approach in atopic dermatitis?
Kägi MK
Dermatology; 2001; 203(4):280-3. PubMed ID: 11752812
[TBL] [Abstract][Full Text] [Related]
38. Leukotriene receptor antagonism may not be effective in atopic dermatitis treatment after all.
Chin WK
J Clin Pharm Ther; 2018 Feb; 43(1):159-162. PubMed ID: 29114905
[TBL] [Abstract][Full Text] [Related]
39. A systematic review on the off-label use of montelukast in atopic dermatitis treatment.
Chin WK; Lee SWH
Int J Clin Pharm; 2018 Oct; 40(5):963-976. PubMed ID: 29777328
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of montelukast in the treatment of atopic dermatitis.
Rahman ML; Choudhury AM; Islam MM
Mymensingh Med J; 2006 Jan; 15(1):85-8. PubMed ID: 16467770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
